Brent Saunders to return as Bausch + Lomb CEO
Reuters
Published Feb 15, 2023 05:57AM ET
Updated Feb 15, 2023 11:11AM ET
(Reuters) -Bausch + Lomb Corp on Wednesday named Brent Saunders, the former chief executive officer of Allergan (NYSE:AGN), as its CEO and chairman of board, marking his return to the Canadian eye-care company after nearly a decade.
Saunders will join Bausch + Lomb on Feb. 16 in an advisory capacity to help with the transition, the company said.
He will take helm on March 6 from Joseph Papa, who last July announced plans to step down as CEO.
The Vaughan, Ontario-based firm said in December that Papa will continue serving as the CEO until at least March 4, 2023.
Bausch + Lomb is in the process of being spun out from Bausch Health Companies, which was formerly known as Valeant Pharmaceuticals (NYSE:BHC).
Saunders has served as the CEO of Botox maker Allergan, until it was acquired by AbbVie Inc (NYSE:ABBV) for $63 billion in 2020, and previously headed Bausch + Lomb until its acquisition by erstwhile Valeant in 2013.
Get The News You Want
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.